http://orcid.org/0000-0003-0584-0685
References
- Davies M. How checkpoint inhibitors are changing the treatment paradigm in solid tumors: what advanced practitioners in oncology need to know. J Adv Pract Oncol 2016;7:498–509.
- Matsuki E, Younes A. Checkpoint inhibitors and other immune therapies for hodgkin and non-hodgkin lymphoma. Curr Treat Options Oncol 2016;17:31.
- Winer A, Bodor NJ, Borghaei H. Identifying and managing the adverse effects of immune checkpoint blockade. J Thorac Dis 2018;10:S480–S489.
- Rudzki JD. Management of adverse events related to checkpoint inhibition therapy. Memo 2018;11:132–137.
- Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol 2016;39:98–106.
- Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29:iv264–iv266.
- Patel AB, Pacha O. Skin reactions to immune checkpoint inhibitors. Adv Exp Med Biol 2018;995:117–129.
- Plachouri KM, Vryzaki E, Georgiou S. Cutaneous adverse events of immune checkpoint inhibitors: a summarized overview. CDS 2019;14:14–20.
- Hassel JC, Heinzerling L, Aberle J, et al. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): evaluation and management of adverse drug reactions. Cancer Treat Rev 2017;57:36–49.
- Curry JL, Tetzlaff MT, Nagarajan P, et al. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol 2017;44:158–176.
- Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. JCO 2018;36:1714–1768.
- Yee C, Thompson JA, Roche P, et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med 2000;192:1637–1644.
- Sibaud V. Dermatologic reactions to immune checkpoint inhibitors. Am J Clin Dermatol 2018;19:345–361.
- Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy-related toxicities, version 1.2019. J Natl Compr Canc Netw 2019;17:255–289.
- Mochel MC, Ming ME, Imadojemu S, et al. Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma. J Cutan Pathol 2016;43:787–791.
- Kaunitz GJ, Loss M, Rizvi H, et al. Cutaneous eruptions in patients receiving immune checkpoint blockade: clinicopathologic analysis of the non-lichenoid histologic pattern. Am J Surg Pathol 2017;41:1381–1389.
- Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 2017;5:95.
- Hua C, Boussemart L, Mateus C, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 2016;152:45–51.
- Teulings HE, Limpens J, Jansen SN, et al. Vitiligo-like depigmentation in patients with stage III–IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. JCO 2015;33:773–781.
- Nakamura Y, Teramoto Y, Asami Y, et al. Nivolumab therapy for treatment-related vitiligo in a patient with relapsed metastatic melanoma. JAMA Dermatol 2017;153:942–944.
- Belum VR, Benhuri B, Postow MA, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 2016;60:12–25.